Literature DB >> 27402130

Epidemiology of Pulmonary Hypertension in Left Heart Disease.

Ashrith Guha1, Javier Amione-Guerra2, Myung H Park3.   

Abstract

Pulmonary hypertension (PH) in the setting of left side heart disease is associated with adverse outcomes. The exact prevalence of PH in the different pathologies that affect the left ventricle, however, is difficult to access with the current literature. The lack of a standard definition of PH in older studies, the different modalities to assess pulmonary artery pressures and the varying disease severity, all account for the great variability in the reported prevalence of PH. PH can accompany heart failure (HF) with reduced (HFrEF) or preserved ejection fraction (HFpEF) as well as mitral and aortic valve disease; in any of these instances it is important to recognize whether the elevation of pulmonary pressures is driven by elevated left ventricular pressures only (isolated post-capillary PH) or if there is an accompanying remodeling component in the pulmonary arterioles (combined post-capillary and pre-capillary PH). The objective of this review is to describe the definitions, prevalence and the risk factors associated with the development of PH in the setting of HFrEF, HFpEF and valvular heart disease.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Epidemiology; Heart failure; Pulmonary hypertension; Valvular heart disease

Mesh:

Year:  2016        PMID: 27402130     DOI: 10.1016/j.pcad.2016.07.001

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  7 in total

Review 1.  Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Authors:  Yen-Chun Lai; Longfei Wang; Mark T Gladwin
Journal:  J Physiol       Date:  2018-12-30       Impact factor: 5.182

Review 2.  Pulmonary Hypertension in Heart Failure.

Authors:  Albert Youngwoo Jang; Su Jung Park; Wook-Jin Chung
Journal:  Int J Heart Fail       Date:  2021-04-21

3.  Pulmonary hypertension in patients with chronic kidney disease: invasive hemodynamic etiology and outcomes.

Authors:  Jared M O'Leary; Tufik R Assad; Meng Xu; Kelly A Birdwell; Eric Farber-Eger; Quinn S Wells; Anna R Hemnes; Evan L Brittain
Journal:  Pulm Circ       Date:  2017-06-29       Impact factor: 3.017

4.  Baseline diastolic pressure gradient and pressure reduction in chronic heart failure patients implanted with the CardioMEMS™ HF sensor.

Authors:  Aaron M Wolfson; Luanda Grazette; Leslie Saxon; Haider Nazeer; David M Shavelle; Rita Jermyn
Journal:  ESC Heart Fail       Date:  2018-03-02

5.  Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels.

Authors:  Annette Dorothea Rieg; Said Suleiman; Nina Andrea Bünting; Eva Verjans; Jan Spillner; Heike Schnöring; Sebastian Kalverkamp; Thomas Schröder; Saskia von Stillfried; Till Braunschweig; Gereon Schälte; Stefan Uhlig; Christian Martin
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

6.  Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.

Authors:  Longfei Wang; Gunner Halliday; Joshua R Huot; Taijyu Satoh; Jeffrey J Baust; Amanda Fisher; Todd Cook; Jian Hu; Theodore Avolio; Dmitry A Goncharov; Yang Bai; Rebecca R Vanderpool; Robert V Considine; Andrea Bonetto; Jiangning Tan; Timothy N Bachman; Andrea Sebastiani; Charles F McTiernan; Ana L Mora; Roberto F Machado; Elena A Goncharova; Mark T Gladwin; Yen-Chun Lai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-04-09       Impact factor: 8.311

7.  Midterm postoperative prognosis of patients with severe left heart valvular disease combined with moderate or severe pulmonary hypertension treated with treprostinil.

Authors:  Ning Xu; Shu-Ting Huang; Kai-Peng Sun; Zeng-Chun Wang; Hua Cao; Qiang Chen
Journal:  BMC Cardiovasc Disord       Date:  2020-11-03       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.